

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/667,289	
			Filing Date	09/18/2003	
			First Named Inventor	Madaline Chirica	
			Art Unit	1647	
			Examiner Name	J. Seharaseyon	
Sheet	1	of	2	Attorney Docket Number	DX01074B


U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/JS/	AT	US-6,756,481 B2	06-29-2004	Chirica, et al.	
/JS/	AU	US-5,888,774	03-30-1999	Delcuve	
/JS/	AV	US-2003/0009018 A1	01-09-2003	Maeda, et al.	
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AW	WO 00/73451	12-07-2000	Schering Corporation		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AX	AGGARWAL, <i>et al.</i> , (Jan. 17, 2003) <i>J. Biol. Chem.</i> 278(3):1910-1914, "Interleukin-23 promotes a distinct CD4 T cell activation state characterized by production of interleukin-17"	
	AY	BECKER, <i>et al.</i> , (Sep. 2003) <i>J. Clin. Invest.</i> 112:693-706, "Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells"	
	AZ	COOPER, <i>et al.</i> , (2002) <i>J. Immunol.</i> , 168:1322-1327, "Mice lacking bioactive IL-12 can generated protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present"	
	BA	CUA, <i>et al.</i> , (Feb. 13, 2003) <i>Nature</i> , 421:744-748, "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain"	
	BB	HAPPEL, <i>et al.</i> , (2003) <i>J. Immunol.</i> 170:4432-4436, "Cutting edge: roles of toll-like receptor 4 and IL-23 in IL-17 expression in response to <i>Klebsiella pneumoniae</i> infection"	
	BC	HÖLSCHER, <i>et al.</i> , (2001) <i>J. Immunol.</i> 167:6957-6966, "A protective and agonistic function of IL-12p40 in mycobacterial infection"	

Examiner Signature	/Jegatheesan Seharaseyon/	Date Considered	10/31/2007
--------------------	---------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, in indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Complete if Known

Application Number	10/667,289
--------------------	------------

Filing Date	09/18/2003
-------------	------------

First Named Inventor	Madaline Chirica
----------------------	------------------

Art Unit	1647
----------	------

Examiner Name	J. Seharaseyon
---------------	----------------

Attorney Docket Number	DX01074B
------------------------	----------

Sheet

?

of

2

Examiner
Initials*Cite
No.¹

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

 τ^2

/JS/

BD

KRAJINA, et al., (2003) *Eur. J. Immunol.* 33:1073-1083, "Colonic lamina propria dendritic cells in mice with CD4⁺ T cell-induced colitis"

RE

MAHAIRAS, *et al.* (1999) *Proc. Nat'l. Acad. Sci. (USA)* 96:9739-9744, "Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome"

BF

NGO, *et al.* (1994) "The Protein Folding Problem and Tertiary Structure Prediction" pp.492-495

BG

OPALINSKA and GEWIRTZ (2002) *Nat. Rev. Drug. Disc.* 1:503, "Nucleic-acid therapeutics: basic principles and recent applications"

BH

PARHAM, *et al.*, (2002) *J. Immunol.* 168:5699-5708, "A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rb1 and a novel cytokine receptor subunit, IL-23R"

BI

1. PETTI and GOMBOTZ (1998) *Trends In Biotech.* 16:343-349, "The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals"

B.J

PHILLIPS (2001) *J. Pharm. and Pharmacology* 53:1169-1174, "The challenge of gene therapy and DNA delivery"

BK

SCOTT, *et al.* (1999) *Nature Genetics* 21:440-443, "The Pendred syndrome gene encodes a chloride-iodide transport protein"

BI

UHLIG and POWRIE (Sep. 2003) *J. Clin. Invest.* 112(5)648-651, "Dendritic cells and the intestinal bacterial flora: a role for localized mucosal immune responses"

BM

WALDVOGEL, Database EMBL Online!, Accession Number AJ308426

BN

WANG, *et al.* (1992) *Genomics* 14(3):666-672, "Molecular cloning and characterization of the rat liver IL-6 signal transducing molecule, gp130"

BO

WELLS (1990) *Biochemistry* 26(37):8509-8517, "Additivity of Mutational Effects in Proteins"

WIEKOWSKI, et al., J. Immunol., 166:7563-7570 (2001), "Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death."

Examiner
Signature

/Jegatheesan Seharaseyon/

Date Considered

10/31/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, in indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.